Agilent Technologies Inc (A)

Nov 11, 2026

Agilent has released its new 5987A GC/MSD system, designed to reduce costly sample reruns by offering faster scanning, a wider detector range, and GC Assist diagnostics. The system aims to mitigate rising carrier gas costs, particularly helium, and improve lab efficiency by consolidating multiple analytical runs into one. Key features include a wider dynamic range to reduce dilution reinjections and simultaneous dSIM/Scan for combined quantitation and library searching.

Nov 6, 2026

Agilent Technologies Inc. (NYSE: A) has completed a $240 million cash acquisition of Proscia, a digital pathology software provider, with potential additional payments up to $30 million based on performance. This acquisition expands Agilent's digital pathology business, integrating AI-enabled software into its clinical diagnostics and life sciences portfolio. Proscia's vendor-agnostic platform and FDA-cleared software enhance Agilent's capabilities in tissue-based diagnostics, pharmaceutical research, and drug development, positioning the company for growth in the estimated $5 billion pathology market.

Nov 5, 2026

Twist Bioscience (NASDAQ: TWST) shares plunged following a report from The Bear Cave, owned by Hunterbrook Media, which suggested the company's stock valuation is inflated compared to its fundamentals and rivals. The report highlighted that despite being an "ordinary lab supplier," Twist trades at a premium, faces significant competition, and questioned if a past 95% stock value drop could recur. The stock was down over 10% following the report.

Nov 5, 2026

Agilent Technologies (NYSE: A) has outperformed the market over the last decade, generating an average annual return of 14.24%. An initial investment of $100 in Agilent stock ten years ago would now be worth $381.67, highlighting the significant impact of compounded returns on cash growth over time.

Nov 4, 2026

Agilent Technologies (A) has seen significant stock gains over the past three years, prompting questions about whether its current US$177.17 share price is justified by its expected cash generation, especially after the acquisition of Proscia and new AI-enabled lab instruments. While discounted cash flow models suggest the stock might be overvalued, the market seems to be factoring in the recurring revenue from software and services, which analysts believe could support its current valuation. Investors are encouraged to consider the company's growth paths, profitability, and management incentives alongside valuation models.

Nov 4, 2026

Agilent Technologies has finalized its acquisition of Proscia for $240 million in cash, with potential additional payments of $30 million. Proscia, a digital pathology software company, will now be part of Agilent's Life Sciences and Diagnostics Markets Group. This acquisition builds on a previous distribution agreement and aims to enhance Agilent's scientific intelligence platform in tissue-based precision medicine by integrating AI-based interpretation with data generation.

Nov 4, 2026

Agilent Technologies Inc. has finalized its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash plus up to $30 million based on future performance. This deal integrates Proscia's vendor-agnostic platform into Agilent's Life Sciences and Diagnostics Markets Group, enhancing its pathology portfolio with AI-enabled workflows and a recurring-revenue software business. The acquisition aims to accelerate drug discovery, companion-diagnostics solutions, and clinical-pathology workflows.

Nov 3, 2026

Agilent Technologies has launched its Altura Ultra Inert HPLC columns, designed for biotherapeutic applications to help biopharmaceutical companies improve reliability in peptide and oligonucleotide therapeutic development and quality control. These columns offer enhanced sensitivity and signal-to-noise ratios compared to competitor products, addressing the biopharma market's need for higher performance and lower limits of detection in complex therapeutic analysis. The technology aims to accelerate discovery and meet regulatory demands through superior chromatographic performance.

Nov 2, 2026

Agilent Technologies Inc. (NYSE: A) shares dropped after the company announced the launch of its new 5987A single quadrupole mass selective detector (MSD) with GC Assist and MassHunter 14 software. This new integrated GC/MS system aims to improve data quality and operational efficiency for laboratories, offering increased scan rates and new operational modes like Dynamic SIM. Despite the new product's features, Agilent's shares fell $1.39 to $173.48 early Monday.

Nov 2, 2026

Agilent Technologies Inc. (NYSE: A) shares declined after the company announced the launch of its new 5987A single quadrupole mass selective detector (MSD) with GC Assist and MassHunter 14 software. This new integrated GC/MS system aims to improve data quality and operational efficiency for laboratories. Despite the product news, Agilent's shares fell $1.39 to $173.48 early on Monday.

Oct 29, 2026

Jacqueline Henderson, the new permanent chief of J&J Vision, is advocating for a unified "lifetime of eye care" approach, integrating the company's contact lens and cataract businesses. This strategic shift comes as rivals like Alcon intensify competition in the US surgical market, and J&J's latest reusable lens awaits US approval. Despite these challenges, Vision sales saw a 5.1% increase in the third quarter, driven by strong performance in both contact lenses and surgical vision.

Oct 28, 2026

DaVita Inc. (NYSE:DVA) is set to report earnings this Thursday. The company beat revenue expectations last quarter but missed full-year EPS guidance. Analysts generally anticipate revenue growth of 2.8% year-on-year for the upcoming quarter, and the stock is trading below its average analyst price target.

Oct 27, 2026

Agilent Technologies (A) raised its fiscal 2026 forecast on August 26, 2026, leading to a 13.9% stock gain since then, outperforming the S&P 500. The stock's price trend remains steady, trading above its 50-day and 200-day averages, with most gains materializing after the initial forecast release. Management increased its sales and earnings outlook for fiscal 2026, driven by a strong third quarter and improving end markets, particularly in pharma.